Kidney Graft Function Under the Immunosuppression Strategies With Low Dose of Neoral(R)(Cyclosporine) and Standard Dose of Myfortic(R)(Enteric-Coated Mycophenolate Sodium) vs. With Conventional Dose of Neoral(R)(Cyclosporine) and Reduced Dose of Myfortic(R)(Enteric-Coated Mycophenolate Sodium) in De Novo Renal Transplant Recipients

Trial Profile

Kidney Graft Function Under the Immunosuppression Strategies With Low Dose of Neoral(R)(Cyclosporine) and Standard Dose of Myfortic(R)(Enteric-Coated Mycophenolate Sodium) vs. With Conventional Dose of Neoral(R)(Cyclosporine) and Reduced Dose of Myfortic(R)(Enteric-Coated Mycophenolate Sodium) in De Novo Renal Transplant Recipients

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2014

At a glance

  • Drugs Mycophenolate sodium (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms MyLowCsA
  • Most Recent Events

    • 05 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top